The request for information (RFI) was submitted to the Senate Finance Committee Minority Staff on August 17, 2026.
Richard G. Frank and Rachel Sachs recently responded to a request for information from Ranking Member Ron Wyden of the Senate Committee on Finance on lowering drug prices, enhancing prescription drug affordability, and bolstering biopharmaceutical innovation in the U.S.
Their response examines policy options ranging from international reference pricing and strengthening the impact of the Medicare Drug Price Negotiation Program to targeted tax incentives for early-stage biotechnology firms.
Related Content
Authors
-
Acknowledgements and disclosures
The authors thank Loren Adler for comments on an earlier draft, Amaya Allen for fact-checking assistance, and Rasa Siniakovas for editorial assistance.
The Brookings Institution is committed to quality, independence, and impact.
We are supported by a diverse array of funders. In line with our values and policies, each Brookings publication represents the sole views of its author(s).
Commentary
Response to Senate Finance Committee request for information on policies for lowering drug prices
August 18, 2026